Prognostic factors | Cox Regression | ||||||
---|---|---|---|---|---|---|---|
Unadjusted A) | Full model B) | Variable selection C) | |||||
HR (95 % CI) | p D) | HR (95 % CI) | p D) | HR (95 % CI) | p D) | ||
ITC | No | Reference | 0.043 | Reference | 0.024 | Reference | 0.005 |
Yes | 2.82 (1.06–7.49) | 3.59 (1.18–10.9) | 4.73 (1.67–13.4) | ||||
Age | (years) | 1.10 (1.03–1.17) | 0.001 | 1.12 (1.03–1.22) | <0.001 | 1.13 (1.05–1.21) | <0.001 |
Gender | male | Reference | 0.260 | Reference | 0.220 | - | - |
female | 0.57 (0.21–1.55) | 0.51 (0.17–1.53) | - | - | |||
Tumor localisation | colonic | Reference | 0.428 | Reference | 0.886 | - | - |
rectosigmoidal | 0.64 (0.21–2.00) | 0.91 (0.24–3.47) | - | - | |||
AJCC stage | I | Reference | 0.569 | Reference | 0.581 | - | - |
II | 1.35 (0.47–3.84) | 1.39 (0.43–4.52) | - | - | |||
Grading | GI/GII | Reference | 0.356 | Reference | 0.952 | - | - |
GIII | 1.62 (0.57–4.62) | 1.04 (0.28–3.84) | - | - | |||
Lymphovascular | No | Reference | 0.182 | Reference | 0.368 | - | - |
invasion | Yes | 2.30 (0.74–7.12) | 2.04 (0.45–9.31) | - | - | ||
Preoperative CEA | <5 μg/l | Reference | 0.304 | Reference | 0.302 | - | - |
levels | ≥5 μg/l | 0.49 (0.11–2.15) | 0.42 (0.07–2.44) | - | - | ||
TotalLNn | (n) | 0.98 (0.94–1.02) | 0.323 | 1.00 (0.95–1.05) | 0.898 | - | - |
SLNn | (n) | 1.00 (0.86–1.15) | 0.954 | 1.02 (0.85–1.22) | 0.850 | - | - |
Adjuvant | No | Reference | 0.976 | Reference | 0.705 | - | - |
Chemotherapy | Yes | 0.98 (0.22–4.33) | 1.47 (0.21–10.4) | - | - |